Nanomanufacturing has offered unprecedented opportunities for drug delivery and therapeutic advancements. This cutting-edge technology involves the precise manipulation and assembly of nanoscale materials to create pharmaceutical products with enhanced properties. In the realm of drug formulation, nanomanufacturing allows for the development of nanoparticles tailored to optimize drug solubility, bioavailability, and targeted delivery. This precision at the molecular level holds promise for improving the efficacy of various pharmaceutical compounds while minimizing side effects.
Furthermore, nanomanufacturing techniques, such as nanoparticle-based carriers and nanoscale fabrication processes, enable the production of innovative drug delivery systems that can traverse biological barriers, delivering therapeutic payloads with remarkable precision. The intersection of nanotechnology and pharmaceuticals not only opens new avenues for therapeutic interventions but also presents challenges related to scalability, regulatory considerations, and safety. As researchers and industry experts delve deeper into the potential of nanomanufacturing, its role in shaping the future of pharmaceuticals becomes increasingly evident, promising a paradigm shift in drug development and patient care.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia